Investors bail out of MDS warrants

Article Abstract:

MDS Proteomics Inc., which is a subsidiary of MDS Inc., is losing institutional investors who are wary of its $82.5 million private placement of special warrants. MDS Proteomics, which is involved in drug development, has sold 3.3 special warrants in anticipation of an initial public offering.

Drugs & Pharmaceuticals, Pharmaceutical and Medicine Manufacturing, Drugs, Pharmaceutical industry

---

MDS IPO could fetch $200-million, analysts say

Article Abstract:

Toronto, Ont.-based MDS Inc. has announced that its proteomics division will launch an initial public offering that is expected to raise between $100 million and $200 million. MDS Proteomics Inc. will launch the IPO in the US and Canada.

---

CryoCath sails IPO in stormy seas

Article Abstract:

Montreal, Ont.-based CryoCath Technologies Inc. has launched an initial public offering, raising about $40 million. CryoCath, which is a biotechnology company, is facing financial volatility in the biosciences sector.

Securities, CRYOCATH TECHNOLOGIES INC.

Similar abstracts:

• Abstracts: Pilots union turf war brews. Air Canada warns workers. Air Canada cuts 3,500 jobs
• Abstracts: Rogers to pay out dividend. CHUM, Rogers still in specialty TV deadlock. Rogers Communications shares fall 11%
• Abstracts: Tobin's exit raises hopes about Voisey's. Inco strikes supply deal in Australia
• Abstracts: Steel makers sound dumping alarm. Stelco loss reflects steel industry woes. CITT throws out galvanized-steel dumping case
• Abstracts: CGI grows-but at what cost? QSC investigating Jitec trades

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.